Compugen to Speak at Antibody Industrial Symposium

Compugen Ltd., an innovative clinical-stage company in cancer immunotherapy and computational target discovery, announced a significant presentation by Pierre Ferré, Ph.D., during the upcoming Antibody Industrial Symposium. This event, scheduled for June 20-21, 2024, in Montpellier, France, will feature a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies. Dr. Ferré, who serves as the Senior Vice President of Preclinical Development and Corporate Operations at Compugen, will present this case study on June 21, 2024.

Compugen is at the forefront of therapeutic discovery and development, leveraging advanced computational technology to identify novel drug targets and biological pathways essential for cancer immunotherapy. The company’s sophisticated approach has led to the creation of two proprietary product candidates. One of these, COM701, is designed as a potential first-in-class anti-PVRIG antibody, while the other, COM902, is a promising best-in-class antibody aimed at targeting TIGIT for treating solid tumors.

Further advancing its innovative pipeline, Compugen has developed rilvegostomig, a PD-1/TIGIT bispecific antibody. The TIGIT component of this bispecific antibody is derived from COM902, demonstrating the interconnectedness of Compugen’s therapeutic strategies. This antibody is currently in Phase 3 development under a collaboration with AstraZeneca, focusing on the development of bispecific and multispecific antibodies.

Compugen's robust early-stage immuno-oncology programs aim to counteract various mechanisms of immune resistance, thereby enhancing the effectiveness of cancer treatments. The most advanced of these programs is COM503, which is in the IND enabling studies phase and has been licensed to Gilead. COM503 holds promise as a first-in-class, high-affinity antibody designed to block the interaction between IL-18 binding protein and IL-18. This action is crucial as it allows natural IL-18 to remain active in the tumor microenvironment, thereby inhibiting cancer growth and improving patient outcomes.

Headquartered in Israel, Compugen also maintains offices in San Francisco, California. The company’s shares are publicly traded on both the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Compugen continues to build on its pioneering computational discovery capabilities, positioning itself as a leader in the field of cancer immunotherapy.

The Antibody Industrial Symposium stands as an influential event in the biotechnology sector, providing a platform for industry leaders to disseminate their latest research and development findings. Dr. Ferré’s presentation is anticipated to shed light on the intricate processes involved in clinical dose selection for antibodies, a crucial aspect of developing effective cancer treatments.

By participating in such high-profile industry events, Compugen not only underscores its commitment to advancing cancer immunotherapy but also highlights its ongoing contributions to scientific and medical communities. These developments reflect the company’s sustained effort to harness computational technology in the fight against cancer, ultimately striving to improve patient care and outcomes in oncology.

In sum, Compugen’s role in the upcoming symposium, along with its continuous advancements in therapeutic development, reinforces its position as a trailblazer in the cancer immunotherapy landscape. Through its innovative approaches and strategic collaborations, the company remains dedicated to discovering and developing novel treatments that hold the potential to transform cancer care.